Basal Cell Carcinoma Archives

European Commission Approves Libtayo for Two Advanced Cancers

Basal Cell Carcinoma, Blockbusters, European Commission, European Union, Hedgehog Pathway Inhibitors, New Indications, Non-Small Cell Lung Cancer (NSCLC), Overall Survival (OS), Regeneron Pharmaceuticals, Sanofi, Therapeutics

Regeneron Pharmaceuticals and Sanofi announced that the European Commission approved the PD-1 inhibitor Libtayo (cemiplimab) for the first-line treatment of adults with non-small cell lung cancer (NSCLC) whose tumor cells have ≥50% PD-L1 expression and no EGFR, ALK or ROS1 aberrations. The EC also approved Libtayo in advanced basal cell carcinoma (BCC).

June 25, 2021/by Andrew Humphreys

Sanofi and Regeneron’s Libtayo Shows Benefit in Basal Cell Carcinoma

Basal Cell Carcinoma, Checkpoint Inhibitors, Clinical Data, Clinical Trials, PD-1 Inhibitors, R&D

Paris-based Sanofi and Tarrytown, New York-based Regeneron Pharmaceuticals announced topline data for the companies’ pivotal Phase II trial of the PD-1 checkpoint inhibitor Libtayo (cemiplimab) in advanced basal cell carcinoma patients that had progressed on or could not tolerate previous hedgehog pathway inhibitor therapies.

May 5, 2020/by Andrew Humphreys